This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Institut Pierre Farré | |
|---|---|
| Name | Institut Pierre Farré |
| Type | Non-profit research and training institute |
| Founded | 1970s |
| Headquarters | Paris, France |
| Region | International |
| Fields | Medical research; pharmaceutical development; public health; clinical practice |
Institut Pierre Farré is a Paris-based institute focused on applied medical research, clinical training, and publication in pharmacology and therapeutic practice. Founded in the late 20th century, the institute has engaged with a wide network of hospitals, universities, regulatory agencies, and professional societies to influence clinical protocols, drug information dissemination, and continuing medical education. Its activities intersect with multiple institutions and individuals across Europe and globally, shaping practice in primary care, hospital medicine, and public health programs.
The institute traces roots to collaborations among clinicians and pharmacists in Paris, influenced by figures associated with Assistance Publique–Hôpitaux de Paris, Collège de France, Sorbonne Université, and early patient safety advocates linked to World Health Organization initiatives. During the 1970s and 1980s it expanded ties with colleagues at Inserm, CNRS, Université Paris Cité, Université Paris-Descartes, Hôpitaux de Paris and noted hospitals such as Hôpital Saint-Antoine, Hôpital Necker–Enfants Malades, Hôpital Cochin and Hôpital Pitié-Salpêtrière. Over subsequent decades the institute established relationships with regulatory and professional bodies including Haute Autorité de Santé, Agence nationale de sécurité du médicament et des produits de santé, European Medicines Agency, Conseil National de l'Ordre des Médecins and international organizations such as Food and Drug Administration and European Commission. Collaborations extended to universities and institutes like University of Cambridge, University of Oxford, Karolinska Institutet, Johns Hopkins University, Harvard Medical School, University of California, San Francisco, Imperial College London, UCL, McGill University, University of Toronto, Heidelberg University, Ludwig Maximilian University of Munich, ETH Zurich, Erasmus University Rotterdam, KU Leuven, University of Barcelona, Universidad Complutense de Madrid, University of Milan, Sapienza University of Rome, Université de Genève, University of Amsterdam, University of Copenhagen, Stockholm School of Economics and research centers such as Institut Pasteur and Centre Léon Bérard.
Institut Pierre Farré aims to produce independent therapeutic information, develop clinical training, and support evidence-based prescribing through collaborations with professional bodies like French National Consultative Ethics Committee, Société Française de Pharmacologie et de Thérapeutique, British Medical Association, American Medical Association, Royal College of Physicians, Royal College of General Practitioners, European Society of Cardiology, European Respiratory Society and patient associations including European Patients' Forum and Médecins Sans Frontières. Activities include clinical audits in partnership with hospitals such as Mayo Clinic, Cleveland Clinic, Mount Sinai Hospital (New York), Massachusetts General Hospital, Royal Brompton Hospital, St Thomas' Hospital and health agencies like Public Health England and Santé publique France. The institute provides drug information services aligned with standards from World Medical Association and ethical frameworks referenced by UNESCO and Council of Europe.
Research outputs span pharmacoepidemiology, adverse drug reaction monitoring, clinical guidelines and therapeutic reviews often cited alongside work from Lancet, The New England Journal of Medicine, British Medical Journal, JAMA, Nature Medicine, Science Translational Medicine, Annals of Internal Medicine, PLOS Medicine and specialty journals of European Respiratory Journal, Circulation, Gastroenterology (journal), Journal of Clinical Oncology, Neurology (journal), Diabetes Care, Rheumatology (Oxford Academic), The Pediatric Infectious Disease Journal and Clinical Infectious Diseases. The institute has produced position papers and monographs referenced by committees within World Health Organization, European Centre for Disease Prevention and Control, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Organisation for Economic Co-operation and Development and national academies including Académie nationale de médecine and Royal Society (United Kingdom). Contributors have included researchers who also publish with teams at Institut Curie, Gustave Roussy, Karolinska University Hospital, John Radcliffe Hospital and Guy's and St Thomas' NHS Foundation Trust.
Training programs target clinicians, pharmacists and allied professionals and are accredited by bodies such as Agence nationale du DPC, European Board for Accreditation in Cardiology, European Board of Medical Specialties, American Board of Internal Medicine, Royal College of Surgeons of England and universities like Université Paris-Saclay and École des Hautes Études en Santé Publique. Courses cover rational prescribing, pharmacovigilance, antibiotic stewardship, chronic disease management, and palliative care with faculty drawn from Institut Pasteur, Institut Gustave Roussy, Hôpitaux Universitaires de Genève, Karolinska Institutet, Mayo Clinic, Mount Sinai School of Medicine, Johns Hopkins Bloomberg School of Public Health and Harvard T.H. Chan School of Public Health.
The institute maintains partnerships with pharmaceutical and biotech units, academic hospitals, and nonprofit organizations including Sanofi, Roche, Novartis, Pfizer, GlaxoSmithKline, AstraZeneca, Bayer AG, Eli Lilly and Company, Johnson & Johnson, Gilead Sciences, Merck & Co., Boehringer Ingelheim and consortia like Innovative Medicines Initiative, European Federation of Pharmaceutical Industries and Associations, Life Sciences Research Network, European University Association and patient groups such as European Heart Network and European Cancer Organisation. Collaborative clinical registries link to networks including EuroHeart, RESPIRE, EMERGE, EUPATI and national data platforms such as SNDS and regional health information systems in partnership with institutions like AP-HP.
Governance comprises a board of directors, scientific advisory board and ethics committee with experts drawn from Académie des sciences, Académie nationale de médecine, European Molecular Biology Organization, World Health Organization, European Commission science services, and leading university hospitals including Hôpital Necker–Enfants Malades, Hôpital Cochin and Hôpital Pitié-Salpêtrière. Legal and financial oversight interacts with French institutions such as Ministry of Solidarity and Health (France), Caisse nationale d'assurance maladie, Haute Autorité de Santé and European oversight by European Medicines Agency structures.
Notable projects include national pharmacoepidemiology studies that informed policy debated in forums like European Parliament, Organisation mondiale de la Santé meetings, and guidelines adopted by European Society of Cardiology and International Society of Nephrology. The institute contributed to antibiotic stewardship programs implemented alongside World Health Organization campaigns, vaccine-safety surveillance linked to European Centre for Disease Prevention and Control and post-marketing studies cited in regulatory decisions by Agence nationale de sécurité du médicament et des produits de santé and Food and Drug Administration. Impact is seen in guideline adoption at hospitals including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Hôpitaux universitaires de Genève and in continuing education recognized by Royal College of Physicians and American Medical Association.
Category:Medical research institutes